EUVIMEDEUVIMED entdecken
Crossref

Bispecific Antibodies in the CAR T-Cell Era: Bridging Therapy, Sequencing, and Emerging Paradigms

Liesl Eibschutz, Nathan Roberts, Emily Ayers

Medical Research Archives · 2025 · 14 (3)

DOI: 10.18103/mra.v14i3.7330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, 2025. Verfasst von Liesl Eibschutz und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delays in accessing CAR T-cell therapy remain a significant barrier for patients with aggressive hematologic malignancies, with many failing to reach infusion due to manufacturing delays, waitlist mortality, comorbidities, and disease progression. Bispecific antibodies, with their off-the-shelf availability, rapid cytoreductive potential, and manageable toxicity, have emerged not only as a promising bridging modality to preserve eligibility and optimize patients before CAR T-cell therapy but also as standalone therapies. This review synthesizes current evidence on bispecific antibodies, including comparative safety/efficacy with CAR T-cell, their toxicity profile, emerging resistance patterns, and, most importantly, their role as a bridging therapy before CAR T-cell treatment.

Zitieren

APA

Eibschutz, L., Roberts, N., & Ayers, E. (2025). Bispecific Antibodies in the CAR T-Cell Era: Bridging Therapy, Sequencing, and Emerging Paradigms. Medical Research Archives, 14(3). https://doi.org/10.18103/mra.v14i3.7330

Vancouver

Eibschutz L, Roberts N, Ayers E. Bispecific Antibodies in the CAR T-Cell Era: Bridging Therapy, Sequencing, and Emerging Paradigms. Medical Research Archives. 2025;14(3). doi:10.18103/mra.v14i3.7330

BibTeX
@article{Eibschutz2025,
  author = {Eibschutz, Liesl and Roberts, Nathan and Ayers, Emily},
  title = {Bispecific Antibodies in the CAR T-Cell Era: Bridging Therapy, Sequencing, and Emerging Paradigms},
  journal = {Medical Research Archives},
  year = {2025},
  volume = {14},
  number = {3},
  doi = {10.18103/mra.v14i3.7330}
}
Kostenlos starten →